SCHEMBL23914877

SCHEMBL23914877

FC(F)COc1cc2cn[nH]c2cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 6/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
TRPV1 Q8NER1 1/20 0.40
NOS1 P29475 2/20 0.39
DYRK1A Q13627 1/20 0.39
AXL P30530 1/20 0.38
CHEK1 O14757 1/20 0.38
S1PR2 O95136 1/20 0.36
TLR8 Q9NR97 1/20 0.36
KCNH2 Q12809 1/20 0.35
FGFR2 P21802 3/20 0.34
FGFR1 P11362 3/20 0.34
MAOB P27338 1/20 0.34
MKNK1 Q9BUB5 1/20 0.33
ROCK2 O75116 1/20 0.33
PIM1 P11309 1/20 0.33
GSK3B P49841 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23915493 0.82 AXL (0.51) TRPA1TRPM8TRPV1NOS1DYRK1A
SCHEMBL23915494 0.80 TRPA1 (0.49) TRPA1TRPM8TRPV1NOS1DYRK1A
SCHEMBL23914876 0.79 TRPA1 (0.49) TRPA1TRPM8TRPV1NOS1DYRK1A
SCHEMBL23909011 0.75 TRPA1 (0.53) TRPA1TRPM8TRPV1NOS1DYRK1A
SCHEMBL29109556 0.74 AXL (0.60) TRPA1TRPM8TRPV1NOS1DYRK1A
SCHEMBL23915491 0.74 TRPA1 (0.52) TRPA1NOS1DYRK1AAXLCHEK1
SCHEMBL3590783 0.71 NOS1 (0.57) TRPA1TRPM8TRPV1NOS1DYRK1A
SCHEMBL24358709 0.71 AXL (0.48) TRPA1TRPM8NOS1DYRK1AAXL
SCHEMBL14312467 0.69 NOS1 (0.50) TRPA1TRPM8TRPV1NOS1DYRK1A
SCHEMBL30932752 0.68 AXL (0.39) TRPA1TRPM8TRPV1NOS1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3649119-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GALAPAGOS NV (BE) 2021-11-03 EP disclosed
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GILEAD SCIENCES, INC. 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS S1PR1, S1PR3, S1PR2 TRPA1 656/4885TRPM8 1596/4885TRPV1 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.